EICHORCondition: Non-Squamous Non-small Cell Lung Cancer · Sponsor: Summit Therapeutics
A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Progressed on or Following Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment (HARMONi)
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| CBCC Global Research | Bakersfield, California, United States | — |
| UC San Diego | La Jolla, California, United States | — |
| University of Southern California | Los Angeles, California, United States | — |
| Valkyrie Clinical Trials | Los Angeles, California, United States | — |
| UCLA Department of Medicine - Hematology/Oncology | Los Angeles, California, United States | — |
| Palo Alto Medical Foundation Research Institute | Mountain View, California, United States | — |
| Providence St. Joseph | Orange, California, United States | — |
| UC Irvine | Orange, California, United States | — |
| Sutter Cancer center | Sacramento, California, United States | — |
| UC DAVIS Comprehensive Cancer Center | Sacramento, California, United States | — |
| Sharp Memorial Hospital | San Diego, California, United States | — |
| California Pacific Medical Center | San Francisco, California, United States | — |
+ 62 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06396065